KP 103 CAS 164650-44-6

Deskripsyon pwodwi:

Non pwodwi: KP 103 CAS NON: 164650-44-6

Sinonim:

(2R, 3R) -2- (2,4-difluorophenyl) -3- (4-methylidenepiperidin-1-yl) -1- (1,2,4-triazol-1-yl) butan-2-ol;

1-Piperidineethanol, α- (2,4-difluorophenyl) -β-methyl-4-methylene-α- (1H-1,2,4-triazol-1-ilmetil) -, (αR, βR) -;

(alphaR, betaR) -alpha- (2,4-Difluorophenyl) -beta-methyl-4-methylene-alpha- (1H-1,2,4-triazol-1-ilmetil) -1-piperidineetanol;

Chimik& Pwopriyete fizik:

Aparans: Blan poud bèj

Egzamen: ≥99.0%

Dansite: 1.26 ± 0.1 g / cm3 (prevwa)

Bouyi Point: 512.2 ± 60.0 ℃ (prevwa)

Depo Tanp .: -20 ℃

Efinaconazole (non komès Jublia ak Clenafin) se yon antifonjik triazòl. Li apwouve pou itilize nan Kanada ak USA kòm yon solisyon 10% aktualite pou tretman onychomycosis (enfeksyon chanpiyon nan klou a). Efinaconazole aji kòm yon inibitè 14α-demethylase.

Nan de esè klinik 17.8% ak 15.2% nan pasyan lè l sèvi avèk efinaconazole yo te geri, konpare ak 3.3% ak 5.5% nan pasyan lè l sèvi avèk yon plasebo.

Efinaconazole se pa espesyalman efikas, men li se kounye a pi bon tretman an aktualite ki disponib, ak pousantaj gerizon de oswa twa fwa pi bon pase pwochen meyè tretman an aktualite, ciclopirox. Li konsidere kòm yon opsyon rezonab pou pasyan ki gen ka twò grav, oswa pasyan ki pa ka pran tretman oral.

Nan 2014, US Food and Drug Administration (FDA) apwouve Nouvo Aplikasyon Dwòg (NDA) pou Jublia," premye triazòl aktualite apwouve pou tretman onikomikoz zong pye yo." Dapre Valeant Pharmaceuticals International Inc CEO J. Michael Pearson yo te akeri Jublia nan achte yo nan Syans Dow famasetik nan 2008.

Si ou enterese nan pwodwi nou yo oswa ou gen nenpòt kesyon, tanpri ou lib pou kontakte nou!

Pwodwi anba patant yo ofri pou R& D objektif sèlman. Sepandan, responsablite final la manti sèlman ak achtè a.

Baj popilè: kp 103 cas 164650-44-6, manifaktirè, founisè, faktori, achte, nan stock

• On: 2-BROMO-1-[4-HYDROXY-3-(HYDROXYMETHYL) PHENYL] ETHAN-1-YON CAS 62932-94-9
• Pwochen: (S)-Amlodipine CAS 103129-82-4